Name | Value |
---|---|
Revenues | 1.6M |
Cost of Revenue | 0.4M |
Gross Profit | 1.3M |
Operating Expense | 15.0M |
Operating I/L | -13.7M |
Other Income/Expense | -0.4M |
Interest Income | 1.4M |
Pretax | -14.2M |
Income Tax Expense | 2.1M |
Net Income/Loss | -14.2M |
scPharmaceuticals Inc. is a pharmaceutical company specializing in the development and commercialization of innovative pharmaceutical products. Its lead product candidate, FUROSCIX, is a formulation of furosemide delivered through an on-body infusor for treating congestion in heart failure patients. The company's product pipeline also includes scCeftriaxone, an antibiotic for treating infections caused by gram-positive and gram-negative organisms, and the scCarbapenem program for treating infections caused by gram-negative organisms. Additionally, scPharmaceuticals Inc. has a development agreement with West Pharmaceutical Services, Inc. for the creation of a single-use SmartDose device.